155 related articles for article (PubMed ID: 25214565)
1. New hope for young breast cancer patients.
Peres J
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214565
[No Abstract] [Full Text] [Related]
2. Fertility preservation in (breast) cancer patients: is it safe?
Wildiers H; Neven P; Amant F; D'hooghe T; Paridaens R
J Clin Oncol; 2006 Nov; 24(33):5335-6; author reply 5337-8. PubMed ID: 17114672
[No Abstract] [Full Text] [Related]
3. GnRH analogue for chemotherapy-induced ovarian damage: too early to say?
Peccatori F; Demeestere I
Fertil Steril; 2009 Aug; 92(2):e33; author reply e34. PubMed ID: 19646600
[No Abstract] [Full Text] [Related]
4. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Pritchard KI
Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
[TBL] [Abstract][Full Text] [Related]
5. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
6. Questioning GnRH analogs for gonadal protection in cancer patients.
Oktay K; Sönmezer M
Fertil Steril; 2009 Aug; 92(2):e32; author reply e34. PubMed ID: 19646599
[No Abstract] [Full Text] [Related]
7. [Hormone therapy for breast cancer].
Saito Y; Suzuki Y; Tokuda Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():543-8. PubMed ID: 17682208
[No Abstract] [Full Text] [Related]
8. Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature.
Hill N; Madarnas Y
Breast Cancer Res Treat; 2011 Aug; 129(1):265-8. PubMed ID: 21541703
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
10. Use of goserelin in the treatment of breast cancer.
Rody A; Loibl S; von Minckwitz G; Kaufmann M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant endocrine therapy in premenopausal women with breast cancer.
González Martín A; de la Cruz S; Márquez R
Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
[No Abstract] [Full Text] [Related]
12. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
[TBL] [Abstract][Full Text] [Related]
13. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
[TBL] [Abstract][Full Text] [Related]
14. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
Badawy A; Elnashar A; El-Ashry M; Shahat M
Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
[TBL] [Abstract][Full Text] [Related]
16. More treatment options for women with hormone receptor-positive breast cancer: guideline update, studies lead to advances in care.
Printz C
Cancer; 2014 Oct; 120(19):2939-40. PubMed ID: 25241884
[No Abstract] [Full Text] [Related]
17. Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.
Chen Y; Zhang R; Yan Y; Li H; Song G
Breast Cancer Res Treat; 2024 Aug; 206(3):543-550. PubMed ID: 38709374
[TBL] [Abstract][Full Text] [Related]
18. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
Sano M; Makino H
Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
[No Abstract] [Full Text] [Related]
19. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
20. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]